Isolated Gastritis Secondary to Immune Checkpoint Inhibitors Complicated by Superimposed Cytomegalovirus Infection.
Date
2022-02-23Journal
ACG Case Reports JournalPublisher
Wolters Kluwer HealthType
Article
Metadata
Show full item recordSee at
https://doi.org/10.14309/crj.0000000000000747http://www.ncbi.nlm.nih.gov/pmc/articles/pmc8869562/
Abstract
Immune checkpoint inhibitors such as nivolumab increase the T-cell destruction of malignancies but can also trigger a broad variety of immune-related adverse events (irAEs). Colitis as an irAE is well-documented, but upper gastrointestinal tract involvement is primarily unrecognized. We present a patient who developed gastritis as an irAE after multiple cycles of nivolumab and initially responded well to steroid therapy but then developed superimposed cytomegalovirus infection. The similarity between both presentations highlights the importance of having a broad differential diagnosis in patients with gastrointestinal complaints treated with immune checkpoint inhibitors and the need for further studies to better characterize gastritis as an irAE.Rights/Terms
© 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology.Identifier to cite or link to this item
http://hdl.handle.net/10713/18129ae974a485f413a2113503eed53cd6c53
10.14309/crj.0000000000000747
Scopus Count
Collections
Related articles
- NIVOLUMAB-INDUCED ACUTE NEUTROPHILIC GASTRITIS: CASE REPORT IN ATERTIARY HOSPITAL.
- Authors: Gómez AO, Ramón MIP, Brotons AB, García NJ, Sala MDP, Macian MC, Sánchez JSV, Sepulcre MFG
- Issue date: 2023 Jan 27